Anna Berglof

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

Journal: British journal of haematology
Published: October 01, 2025

Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in BTK/Tec double deficient X-linked agammaglobulinemia model.

Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in BTK/Tec double deficient X-linked agammaglobulinemia model.

Journal: RSC chemical biology
Published: December 15, 2024

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function.

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function.

Journal: Blood advances
Published: January 18, 2024

BTKbase, Bruton Tyrosine Kinase Variant Database in X-Linked Agammaglobulinemia: Looking Back and Ahead.

BTKbase, Bruton Tyrosine Kinase Variant Database in X-Linked Agammaglobulinemia: Looking Back and Ahead.

Journal: Human mutation
Published: February 21, 2023

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.

Journal: Frontiers in cell and developmental biology
Published: November 18, 2020

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.

Journal: HemaSphere
Published: November 10, 2020

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

Journal: Leukemia
Published: June 26, 2020

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Journal: Blood advances
Published: December 06, 2019

Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Journal: British journal of haematology
Published: February 25, 2018

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.

Journal: Leukemia
Published: November 14, 2015

Targets for Ibrutinib Beyond B Cell Malignancies.

Targets for Ibrutinib Beyond B Cell Malignancies.

Journal: Scandinavian journal of immunology
Published: May 15, 2015

Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Journal: Current allergy and asthma reports
Published: February 02, 2015
Showing 1-12 of 14

Last Updated: 09/26/2026